US Bancorp DE Sells 697 Shares of Balchem Co. (NASDAQ:BCPC)

US Bancorp DE reduced its holdings in Balchem Co. (NASDAQ:BCPC) by 7.9% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 8,083 shares of the basic materials company’s stock after selling 697 shares during the period. US Bancorp DE’s holdings in Balchem were worth $1,423,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. nVerses Capital LLC bought a new position in Balchem during the third quarter worth $35,000. Bessemer Group Inc. grew its position in Balchem by 568.9% in the 1st quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company’s stock worth $47,000 after purchasing an additional 256 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Balchem by 73.4% during the 3rd quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company’s stock worth $148,000 after purchasing an additional 356 shares during the period. Blue Trust Inc. raised its position in shares of Balchem by 642.5% during the third quarter. Blue Trust Inc. now owns 839 shares of the basic materials company’s stock valued at $148,000 after buying an additional 726 shares during the last quarter. Finally, TD Asset Management Inc bought a new stake in shares of Balchem in the second quarter valued at about $200,000. 87.91% of the stock is currently owned by institutional investors and hedge funds.

Balchem Stock Performance

NASDAQ BCPC opened at $176.63 on Friday. The stock has a market cap of $5.74 billion, a P/E ratio of 47.48, a PEG ratio of 5.28 and a beta of 0.65. The company has a quick ratio of 1.90, a current ratio of 2.98 and a debt-to-equity ratio of 0.21. Balchem Co. has a twelve month low of $116.84 and a twelve month high of $186.03. The company’s 50-day simple moving average is $172.07 and its 200 day simple moving average is $163.86.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. HC Wainwright boosted their price target on Balchem from $185.00 to $190.00 and gave the company a “buy” rating in a research note on Monday. StockNews.com upgraded Balchem from a “hold” rating to a “buy” rating in a research report on Monday, October 28th.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.